Celanese Corp. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This filing covers the quarterly period ended March 31, 2026. Celanese Corporation is a global chemical and specialty materials company operating primarily through two segments: Engineered Materials (high-performance polymers) and Acetyl Chain (intermediate chemicals). The company is currently focused on deleveraging, cost optimization, and managing a challenging global demand environment.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $2,337 million | $2,389 million |
| Gross Profit | $468 million | $474 million |
| Operating Profit | $214 million | $165 million |
| Net Earnings (Attributable to Celanese) | $44 million | ($24 million) Loss |
| Diluted EPS | $0.40 | ($0.22) |
| Operating Cash Flow | $76 million | $37 million |
| Total Debt | $12,554 million | $12,598 million |
| Cash and Equivalents | $1,758 million | $951 million |
| Operating Margin | 9.2% | 6.9% |
Material Changes vs. Prior Period
- Profitability Turnaround: The company returned to profitability with $44 million in net earnings, compared to a $24 million loss in Q1 2025. Operating profit increased 30% to $214 million.
- Asset Disposition: A significant driver of the improvement was a $50 million gain from the sale of the Micromax business to Element Solutions Inc. for $493 million.
- Revenue Decline: Net sales decreased 2% ($52 million) year-over-year, driven by lower volumes and pricing in the Acetyl Chain segment due to global demand weakness and competitive dynamics.
- Cash Position: Cash and cash equivalents increased by $495 million to $1.76 billion, bolstered by the Micromax sale proceeds and improved operating cash flow.
- Restructuring: Restructuring charges were $20 million, down from $31 million in the prior year, though the company announced new plant closures (Lanaken, Belgium; Sakra, Singapore) with expected future costs.
Guidance, Outlook, and Risks
- Capital Allocation: The company has paused its share repurchase program and reduced its quarterly dividend by approximately 95% (to $0.03/share) to prioritize deleveraging.
- Capital Expenditures: Total capital expenditures for 2026 are expected to be between $300 million and $350 million, focused on maintenance and productivity improvements.
- Deleveraging Strategy: Management expects to continue deleveraging through cost reductions, operational improvements, and potential opportunistic dispositions of other assets.
- Risks and Contingencies:
- Plant Closures: Additional exit costs of $100 million are expected for the Lanaken, Belgium facility closure through 2027. A new closure was announced for the Sakra, Singapore unit.
- Legal Proceedings: Ongoing litigation regarding the Diamond Alkali Superfund Site (Lower Passaic River) and European Commission competition law claims regarding ethylene purchases.
- Tax Audits: Active audits in the U.S., Mexico, Canada, and Germany; a resolution with the IRS is expected by the end of 2026.
- Market Conditions: Continued macroeconomic weakness in key end markets (automotive, construction) and raw material price volatility.
Investor Verification Checklist
- Debt Covenants: Verify compliance with financial ratio maintenance covenants in credit facilities, given the high leverage and recent credit rating downgrades.
- Disposition Proceeds: Confirm the final net proceeds from the Micromax sale and the timing of cash deployment toward debt reduction.
- Restructuring Costs: Monitor the actual cash outflow for the Lanaken and Sakra plant closures against the estimated $100 million+ in future costs.
- Acetyl Chain Margins: Assess the sustainability of margins in the Acetyl Chain segment given the reported supply/demand imbalance and pricing pressure.
- Tax Resolution: Track the finalization of the IRS audit resolution and potential impacts on the effective tax rate.